COVID-19ワクチンの市場規模、動向、分析：疾患の概要、疫学、アンメットニーズと機会、治療法の見通し、パイプラインの評価、臨床試験戦略、予測（～2026年）

当レポートでは、COVID-19ワクチン市場について調査分析し、疾患の概要、疫学、現在の治療オプション、アンメットニーズと機会、研究開発戦略、パイプラインの評価、市場見通しなどの情報を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 疾患の概要

• COVID-19の流行とワクチン開発のタイムライン
• COVID-19のSWOT分析
• SARS-CoV-2の分類
• COVID-19の病因と病態生理学

第4章 疫学

第5章 現在の治療オプション

• 初期のSARS-CoV-2ワクチン接種の情勢（2020年～2021年）
• 現在のSARS-CoV-2ワクチン接種の情勢
• 主要7市場における上市/承認済みCOVID-19ワクチン
• 製品プロファイル
• COVID-19の治療法の情勢

第6章 アンメットニーズと機会

• COVID-19ワクチン接種におけるアンメットニーズ

第7章 研究開発戦略

• 臨床試験デザインの動向
• COVID-19ワクチンに対する取引決定の動向（2020年～現在）

第8章 パイプラインの評価

• COVID-19ワクチンのパイプラインの概要
• COVID-19ワクチン：臨床試験（フェースII/III）の概要
• 主要7市場の主なパイプラインワクチン候補

第9章 市場見通し

• COVID-19ワクチン：市場予測
• COVID-19ワクチン：市場の促進要因と障壁

第10章 付録

第11章 連絡先

Abstract

The report provides an in-depth assessment of the COVID-19 market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

COVID-19 is a disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in the city of Wuhan, China in December 2019. The initial outbreak is thought to have originated in an animal market and spread rapidly throughout the city and region. By late March 2020, global COVID-19 cases surpassed 100,000, and the WHO officially declared the outbreak a global pandemic. To date, more than 767 million confirmed COVID-19 cases have been documented around the globe, along with over 6.9 million COVID-19-associated deaths.

The virus spreads mainly through respiratory droplets released by an infected person to people in close contact. Symptoms can range from mild to severe and may include fever, chills, cough, sore throat, shortness of breath, fatigue, muscle aches, headache, congestion, nausea or vomiting, diarrhea, confusion, and loss of taste or smell. A wide range of other less common symptoms have also been reported. Complications of COVID-19 include acute respiratory distress syndrome (ARDS), pneumonia, blood clots, acute kidney injury (AKI), and multi-organ failure. COVID-19 has also been linked to various long-term symptoms that may last for weeks, months, or years post infection. This condition is referred to as "long COVID". Common symptoms include fatigue, headaches, "brain fog", changes in smell and/or taste, cough, difficulty sleeping, and anxiety. Research is currently ongoing to better understand the condition and how to approach treatment.

The development of COVID-19 vaccines occurred at an unprecedented speed. The first mRNA Phase III vaccine efficacy data was presented by Pfizer/BioNTech and Moderna seven months after Phase I clinical trial initiation, with these becoming the first of the COVID-19 vaccines to gain authorization for use by December 2020. The rapid development and authorization of mRNA-based vaccines in response to the COVID-19 pandemic marks a critical milestone for scientific research and the vaccine space.

Globally, over 5 billion individuals are now fully vaccinated with a primary vaccination series, with over 13.4 billion cumulative vaccine doses administered.

Key Highlights

• Report deliverables include a Pdf and an Excel-based forecast model
• Forecast includes the 7 major markets (7MM)
• Forecast covers the period 2021-2026

Scope

• Overview of Coronavirus disease 2019 (COVID-19) including classification of SARS-CoV-2, etiology, pathophysiology, and epidemiology of COVID-19 and timeline of COVID-19 outbreak and vaccine development.
• Current treatment options including product profiles for COVID-19 vaccines authorized in the 7MM.
• Analysis of unmet needs and R&A strategies within the COVID-19 market.
• Pipeline analysis including product profiles for leading vaccine candidates in the 7MM.
• COVID-19 vaccines market outlook including revenue breakdown by market in 2021 and 2026, revenue breakdown by vaccine type in 2021 and 2026, revenues for leading vaccine products in 2021 and 2026.

Reasons to Buy

• Understand the trends shaping and driving the COVID-19 vaccines market
• Identify the innovative technologies and key players leading the COVID-19 vaccines field
• Recognize gaps and areas of unmet need within the COVID-19 vaccines market
• Determine the current and future outlook for COVID-19 vaccines according to key opinion leaders (KOLs)
• Track COVID-19 vaccine sales from 2021-2026

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Abbreviations
• 1.3 Related Reports

2 Executive Summary

3 Disease Overview

• 3.1 Timeline of COVID-19 Outbreak and Vaccine Development
• 3.2 COVID-19 Vaccines SWOT Analysis
• 3.1 Classification of SARS-CoV-2
• 3.2 Etiology and Pathophysiology of COVID-19

4 Epidemiology

5 Current Treatment Options

• 5.1 The Early SARS-CoV-2 Vaccination Landscape: 2020-2021
• 5.2 The Current SARS-CoV-2 Vaccination Landscape
• 5.3 Marketed/Authorized COVID-19 Vaccines in the 7MM
• 5.4 Product Profiles
• 5.5 COVID-19 Therapeutic Landscape

6 Unmet Needs and Opportunities

• 6.1 Unmet Needs in COVID-19 Vaccination

7 R&D Strategies

• 7.1 Trends in Clinical Trial Design
• 7.2 Trends in Deal-Making for COVID-19 Vaccines (2020-Present)

8 Pipeline Assessment

• 8.1 COVID-19 Vaccines Pipeline Overview
• 8.2 COVID-19 Vaccines: Clinical Trials (Phase II/III) Overview
• 8.3 Leading Pipeline Vaccine Candidates in the 7MM

9 Market Outlook

• 9.1 COVID-19 Vaccines: Market Forecast
• 9.2 COVID-19 Vaccines: Market Drivers and Barriers

10 Appendix

• 10.1 Primary Research: KOL Information
• 10.2 Bibliography
• 10.3 About the Authors

11 Contact Us